Want to see NL:PHARM full AI Analyst Report?
PHARM Stock Chart & Stats
€1.61
-€0.03(-3.69%)
At close: 4:00 PM EST
€1.61
-€0.03(-3.69%)
Day’s Range― - ―
52-Week Range€0.84 - €1.82
Previous CloseN/A
Volume8.99M
Average Volume (3M)19.18M
Market Cap
€811.12M
Enterprise Value€958.34
Total Cash (Recent Filing)€170.72M
Total Debt (Recent Filing)€116.08M
Price to Earnings (P/E)67.3
Beta0.94
Next Earnings
Jul 30, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding707,781,250
10 Day Avg. Volume15,825,784
30 Day Avg. Volume19,178,179
Financial Highlights & Ratios
PEG Ratio-2.78
Price to Book (P/B)3.72
Price to Sales (P/S)2.74
P/FCF Ratio20.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)€403.52M
Bulls Say, Bears Say
Bulls Say
Cash Generation StrengthSustained positive operating and free cash flow represents a durable fundamental strength: reliable internal funding reduces reliance on dilutive financing, supports R&D and launch activities, and provides operating flexibility to weather near-term revenue variability.
Improving Balance Sheet & LiquidityMaterial deleveraging and a stronger balance sheet boost financial resilience over the medium term. Lower leverage and available cash decrease refinancing risk, enable continued pipeline investment and launch spending, and give management optionality through execution cycles.
Commercial & Regulatory Momentum For JoenjaRapid Joenja growth combined with regulatory progress and planned international rollouts is a structural positive: approvals and geographic expansion broaden addressable market for a chronic therapy, offering a durable new revenue stream that can offset HAE franchise pressures over time.
Bears Say
RUCONEST Structural Demand RiskRUCONEST remains a core revenue driver; a 15% decline and inventory/ex‑US exit impacts highlight durable demand and channel risks. New oral entrants and changing specialty pharmacy behaviors could permanently erode volumes absent clear clinical or access advantages.
Joenja Concentration & Commercialization RiskAlthough fast-growing, Joenja is still small vs. total sales; long-term upside hinges on regulatory approvals, diagnostic rates and successful rollouts. Execution or approval delays would materially limit diversification and prolong dependence on RUCONEST.
Modest Profitability And Limited ReturnsDespite very high gross margins, operating and net margins remain thin and revenue is slightly down, implying limited returns on capital. Sustained margin expansion and revenue re‑acceleration are required to translate cash generation into durable, higher returns for investors.
Pharming Group News
PHARM FAQ
What was Pharming Group’s price range in the past 12 months?
Pharming Group lowest stock price was €0.84 and its highest was €1.82 in the past 12 months.
What is Pharming Group’s market cap?
Pharming Group’s market cap is €811.12M.
When is Pharming Group’s upcoming earnings report date?
Pharming Group’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Pharming Group’s earnings last quarter?
Pharming Group released its earnings results on May 07, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of €0 by -€0.006.
Is Pharming Group overvalued?
According to Wall Street analysts Pharming Group’s price is currently Overvalued.
Does Pharming Group pay dividends?
Pharming Group does not currently pay dividends.
What is Pharming Group’s EPS estimate?
Pharming Group’s EPS estimate is <0.01.
How many shares outstanding does Pharming Group have?
Pharming Group has 707,781,250 shares outstanding.
What happened to Pharming Group’s price movement after its last earnings report?
Pharming Group reported an EPS of -€0.006 in its last earnings report, missing expectations of €0. Following the earnings report the stock price went down -25.806%.
Which hedge fund is a major shareholder of Pharming Group?
Currently, no hedge funds are holding shares in NL:PHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharming Group
Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, Europe, and other international markets, focus on addressing rare diseases and critical unmet medical needs. The company's flagship product, Ruconest, is a recombinant human C1 esterase inhibitor prescribed for managing acute attacks of hereditary angioedema. Pharming's development pipeline also encompasses rhC1INH, which is under investigation for potential applications in pre-eclampsia, acute kidney injury, and COVID-19. Furthermore, they are progressing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor, for individuals afflicted with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases. The company maintains significant partnerships, including a development and license agreement with Novartis and a strategic alliance with Orchard Therapeutics plc. This latter collaboration involves the research, development, manufacture, and commercialization of OTL-105, an experimental ex-vivo autologous hematopoietic stem cell gene therapy designed to treat hereditary angioedema.